A probable neuroleptic effect on platelet monoamine oxidase in chronic schizophrenic patients.
Platelet monoamine oxidase activity (MAO) was studied serially over time in 16 chronic schizophrenic patients when medication free and then when medicated. Thirteen of the 16 patients had significant decreases in platelet MAO activity following neuroleptic drug treatment. The change in MAO activity was found to be correlated with response to treatment and to dose of medication.
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001792:Blood Platelets / Q000201:enzymology*; D002908:Chronic Disease; D003864:Depression, Chemical; D005260:Female; D005476:Fluphenazine / Q000627:therapeutic use; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008995:Monoamine Oxidase / Q000097:blood*; D012559:Schizophrenia / Q000188:drug therapy*; D014268:Trifluoperazine / Q000627:therapeutic use
D014150:Antipsychotic Agents; D014268:Trifluoperazine; D008995:Monoamine Oxidase; D006220:Haloperidol; D005476:Fluphenazine